Screener
NovoCure NVCR Q3 2026 earnings
Reported October 29, 2026 · Before market open
Revenue$193.4MBeat by $11.1M
EPS-$0.09Beat by $0.14
Revenue estimate$182.3M
EPS estimate-$0.23
“Novocure's strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies. We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
FAQ
- When did NovoCure report Q3 2026 earnings?
- NovoCure (NVCR) reported Q3 2026 earnings on October 29, 2026 before market open.
- What were NovoCure's Q3 2026 revenue and EPS?
- NovoCure reported revenue of $193.4M and eps of $-0.09 for Q3 2026.
- Did NovoCure beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $182.3M by $11.1M. EPS beat the consensus estimate of $-0.23 by $0.14.
- How did NovoCure's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 15.7% from $167.2M a year earlier and eps grew 72.7% from $-0.33.
- Where can I find NovoCure's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001645113-26-000081) and the 10-Q periodic report (0001645113-26-000080) directly on SEC EDGAR. The filing index links above go to sec.gov.
